Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Rosemary (<i>Rosmarinus officinalis</i> L.) and nervous system disorders: New findings on its neuroprotective properties

Vafadar Moradi E., Rezvani Kakhki B., Yazdanpanah Z., Jalali J., Ghasemzadeh Rahbardar M.

Narrative Review on Neuroinflammation, Chronic Inflammation, published in Iran J Basic Med Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Iran J Basic Med Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42004516
PMCID
PMC13090973
DOI
10.22038/ijbms.2025.88710.19158

Abstract (original English)

Rosemary ( Rosmarinus officinalis L.) has gained recognition for its neuroprotective potential, offering therapeutic benefits for various nervous system disorders. Its main components, including rosmarinic acid, carnosic acid, and ursolic acid, exhibit anti-oxidant, anti-inflammatory, neurotransmitter-modulating, and mitochondrial-stabilizing effects. This updated narrative review explores recent advancements in the mechanisms of action of rosemary and its therapeutic applications in various neurodegenerative diseases. Peer-reviewed studies published between 2020 and 2025 were analyzed using electronic databases, including Scopus, Google Scholar, and PubMed. Research assessing the pharmacological properties of rosemary and its main components, molecular pathways, and clinical implications was reviewed to provide a comprehensive evaluation of its neuroprotective potential.Findings reinforce the neuroprotective potential of rosemary and its main components in Alzheimer's disease, anxiety, depression, epilepsy, pain, and Parkinson's disease. They modulate key molecular pathways, including NF-κB, Nrf2, BDNF, NO/cGMP/KATP, and autophagic clearance, leading to reduced oxidative stress, neuro-inflammation, and apoptosis. They also affect neurotransmitter balance and protein aggregation. The ability of these compounds to enhance cholinergic activity, stabilize mitochondrial integrity,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research